Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity
When semaglutide was tested in obesity trials, participants lost an average of about 15% of their body weightfar exceeding the results seen with earlier anti-obesity drugs
Metabolism 1980
Currently, no medications are approved for obesity treatment in children younger than 12 years, but a randomized controlled trial of 82 patients 6 to 12 years of age found that liraglutide resulted in an estimated BMI reduction of 7% compared with placebo, suggesting potential future applications
US$ 21.57
US$ 23.98
US$ 21.71
